Form 4: Rani Therapeutics Holdings CEO Sells Shares
Insider Transaction (Form 4)
Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., sold 8,014 shares of common stock on December 27, 2024 for $1.41 per share.
Summary
- Open-market sale: disposed of 8,014 Class A Common Stock at $1.41 ($11,300) on December 27, 2024; holds 486,737 after (Direct).
- Tax/exercise-price withholding: disposed of 9,076 Class A Common Stock at $0.55 ($4,992) on June 27, 2025; holds 477,661 after (Direct).
- Tax/exercise-price withholding: disposed of 9,077 Class A Common Stock at $0.48 ($4,357) on September 27, 2025; holds 468,584 after (Direct).
- Tax/exercise-price withholding: disposed of 7,906 Class A Common Stock at $1.40 ($11,068) on December 27, 2025; holds 460,678 after (Direct).
- Tax/exercise-price withholding: disposed of 8,916 Class A Common Stock at $1.13 ($10,075) on March 22, 2026; holds 451,762 after (Direct).
- Tax/exercise-price withholding: disposed of 9,099 Class A Common Stock at $0.81 ($7,370) on March 27, 2026; holds 442,663 after (Direct).
- Tax/exercise-price withholding: disposed of 7,927 Class A Common Stock at $0.74 ($5,866) on June 27, 2026; holds 434,736 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $11,300 of stock on the open market.
Insider Transactions
Talat Imran — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2024-12-27 | Open-market sale | Class A Common Stock | 8,014 | $1 | $11.3K | 486,737 |
| 2025-06-27 | Tax/exercise-price withholding | Class A Common Stock | 9,076 | $1 | $5.0K | 477,661 |
| 2025-09-27 | Tax/exercise-price withholding | Class A Common Stock | 9,077 | $0 | $4.4K | 468,584 |
| 2025-12-27 | Tax/exercise-price withholding | Class A Common Stock | 7,906 | $1 | $11.1K | 460,678 |
| 2026-03-22 | Tax/exercise-price withholding | Class A Common Stock | 8,916 | $1 | $10.1K | 451,762 |
| 2026-03-27 | Tax/exercise-price withholding | Class A Common Stock | 9,099 | $1 | $7.4K | 442,663 |
| 2026-06-27 | Tax/exercise-price withholding | Class A Common Stock | 7,927 | $1 | $5.9K | 434,736 |
Key Dates
| Date | Description |
|---|---|
| 2024-12-27 | Open-market sale (8,014 shares) |
| 2025-06-27 | Tax/exercise-price withholding (9,076 shares) |
| 2025-09-27 | Tax/exercise-price withholding (9,077 shares) |
| 2025-12-27 | Tax/exercise-price withholding (7,906 shares) |
| 2026-03-22 | Tax/exercise-price withholding (8,916 shares) |
| 2026-03-27 | Tax/exercise-price withholding (9,099 shares) |
| 2026-06-27 | Tax/exercise-price withholding (7,927 shares) |
Keywords
insider transaction, Form 4, RANI, Rani Therapeutics Holdings, Inc., bearish, Talat Imran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.